（商品説明）

細菌のＤＮＡ合成を阻害し、増殖を抑制する新しいタイプの抗生物質。

グラム陰性菌、グラム陽性菌、マイコプラズマなど幅広い抗菌活性を持っており耐性菌の発現率も低いため、小動物の感染症治療に幅広く使われています。

皮膚、口、呼吸器系、尿路系の感染症治療に主に用いられています。

*在庫保有不可能商品ですので、都度ヨーロッパよりの取り寄せ発送となります。

ご注文頂いてからお手元に届くまで２～３週間程度かかります。

（使用法）

3-4.5mg/kgを目安に１日１回投与。

（投与量目安）

（１）3-4.5kg:1錠

（２）5-7.5kg:1+1/2

（３）7.5-10kg:2錠

（４）10-15kg:3錠

（投与期間目安）

（１）表在性膿皮症：14 - 21日間

（２）深い膿皮症：14 - 35日間

（３）傷感染症：7日間

（４）尿路の急性感染症：7 - 21日間

（５）歯肉と歯周組織のひどい感染症：7日間

投与中断や継続は投与開始後の改善状況を鑑みて適切な量と投与期間を決めて下さい。

使用や投与量、投与量に関し不安のある方は獣医師と相談の上、ご使用下さい。

＊生後１２か月以内の小型犬、猫には投与しないで下さい。

＊生後１８か月以内の大型犬には投与しないで下さい。

（使用期限）

ご注文時より１年以上有効

-------------------------------------------------------------------------------------------------------------------------------------------------------------

Veraflox 60mg 7tablets

Presentation

Veraflox 15 mg tablets are brownish single scored tablets for oral administration to cats and dogs, they contain 15 mg pradofloxacin and have been marked with “P15” on one side.

Veraflox 60 mg tablets are brownish single scored tablets for oral administration to dogs, they contain 60 mg pradofloxacin and have been marked with “P60” on one side.

Veraflox 120 mg tablets are brownish single scored tablets for oral administration to dogs, they contain 120 mg pradofloxacin and have been marked with “P120” on one side. 

Uses

Cats: Treatment of acute infections of the upper respiratory tract caused by susceptible strains of Pasteurella multocida, Escherichia coli and the Staphylococcus intermedius group (including S. pseudintermedius).

Dogs: Treatment of:

· wound infections caused by susceptible strains of the Staphylococcus intermedius group (including S.pseudintermedius)

· superficial and deep pyoderma caused by susceptible strains of the Staphylococcus intermedius group (including S. pseudintermedius)

· acute urinary tract infections caused by susceptible strains of Escherichia coli and the Staphylococcus intermedius group (including S. pseudintermedius) and

· as adjunctive treatment to mechanical or surgical periodontal therapy in the treatment of severe infections of the gingiva and periodontal tissues caused by susceptible strains of anaerobic organisms, for example Porphyromonas spp. and Prevotella spp.

Dosage and administration

Administration is via the oral route.

The recommended dose is 3.0 mg/kg bodyweight of pradofloxacin once daily. Due to the available tablet sizes the resulting dose range is 3.0 to 4.5 mg/kg bodyweight according to the following tables. To ensure a correct dosage, bodyweight should be determined as accurately as possible to avoid underdosing.4